Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regentis BiomaterialsRGNT -20.43%14 EV-to-FCF is -9.61 as of Jul. 14, 2026. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Regentis Biomaterials ranks worse than 241545.65% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Regentis Biomaterials's Enterprise Value is $13.21 Mil.
Regentis Biomaterials's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.38 Mil. Therefore, Regentis Biomaterials's EV-to-FCF for today is -9.61.
The historical rank and industry rank for Regentis Biomaterials's EV-to-FCF or its related term are showing as below:
RGNT'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.23 Med: 0 Max: 0
Current: -9.61
RGNT's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.445
vs RGNT: -9.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regentis Biomaterials's PE Ratio (TTM) for today is calculated as:
Regentis Biomaterials's share price for today is $2.761.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.644.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regentis Biomaterials EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Regentis Biomaterials's EV-to-FCF falls into.
Regentis Biomaterials's current Enterprise Value is $13.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regentis Biomaterials (RGNT) has a EV-to-FCF of -9.61 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Regentis Biomaterials and its competitors. According to the industry distribution chart, Regentis Biomaterials ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Regentis Biomaterials' EV-to-FCF too high?
Regentis Biomaterials' current EV-to-FCF is -9.61. Based on the distribution chart, Regentis Biomaterials ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' EV-to-FCF compare to HBIO and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #999999 out of 414 companies for EV-to-FCF. This places Regentis Biomaterials in the lower half of its industry. The industry median EV-to-FCF is 23.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.45, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Regentis Biomaterials and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current EV-to-FCF is -9.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current EV-to-FCF of -9.61. The current EV-to-FCF is -9.61. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current EV-to-FCF is -9.61 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score
Get the complete analysis for RGNT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGNT has been successfully added to your 
